UroAlert - GU Oncology Weekly

September 11, 2025

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Is it prime time for stent-less robotic radical cystectomy? A scoping review.

Non-invasive bladder cancer detection: Identification of a urinary volatile biomarker panel using GC-MS metabolomics and machine learning.

Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.

INLEXZO™ (Gemcitabine Intravesical System) Is FDA Approved and Is Indicated for the Treatment of Adult Patients with BCG-unresponsive NMIBC with Carcinoma in Situ (CIS), with or Without Papillary Tumors

Routine annual imaging does not aid in diagnosing new functional complications more than five years after RC with ileal conduit.

Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.

Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer.

AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in Bladder Cancer via Multi-parametric Imaging: A Systematic Review and Meta-analysis.

CG Oncology Completes Enrollment in PIVOT-006

Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma.

The Dynamic Field of Perioperative Treatment for Localized Muscle-Invasive Bladder Cancer: A Review of the Current Research Landscape.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.

Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.

Prognostic Significance of Pathologic Response to Neoadjuvant Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder with Histologic Subtype - Beyond the Abstract

Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis - Beyond the Abstract

Impact on Oncological Outcomes of Detrusor Muscle Absence in pTaHG Urothelial Carcinoma of the Bladder? the End of the "Jump" of the Lamina Propria Layer Myth - Beyond the Abstract

Oncologic Outcomes of Neoadjuvant Chemotherapy and Lymph Node Dissection with Partial Cystectomy for Muscle-Invasive Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Interplay of PD-L1, FOXP3, and CD8 in the Immune Microenvironment of Penile Squamous Cell Carcinoma: Expression Profiles and Correlations.

Human papillomavirus vaccination and its effect on genital men's health. Considerations for a public health strategy.

Survivin and Ki-67 Immunohistochemical Expression in Penile Squamous Cell Carcinoma: Clinicopathological Features and Overall Survival - Beyond the Abstract

Single-Port Antegrade Robotic Lymphadenectomy: A Novel Minimally Invasive Approach to Treat Lymph Nodes in Men with Penile Cancer - Beyond the Abstract

Renal Cancer

Lipid metabolism of clear cell renal cell carcinoma predicts survival and affects intratumoral CD8 T cells.

Management of renal cancer with inferior vena cava extension over 30 years: a bi-centric study.

The Safety Profile of Belzutifan in Renal Tumors: Real-World Data from a Tertiary Academic Center.

The Nephrologist's Perspective in Evaluation and Management of Localized Renal Masses: Core Curriculum 2025.

Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer.

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial.

Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124).

Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma.

Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.

Proposed tripartite classification of T1 renal cell carcinoma: Comparison with current binary system.

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland.

Prostate Cancer

Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024).

Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.

Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.

Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.

Impact of sociodemographic and socioeconomic factors on functional and health-related quality of life outcomes 24 months after radical prostatectomy.

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer.

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001

Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist.

Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.

Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans.

Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review.

Outcomes of robot-assisted radical prostatectomy with novel robotic platforms vs da Vinci multiport systems: a systematic review and network meta-analysis.

YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice.

Chemosensor receptors are lipid-detecting regulators of macrophage function in cancer.

Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC.

NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling.

Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy.

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications.

Association Between Race and Detection of Clinically Significant Prostate Cancer in Transperineal and Transrectal Biopsies.

Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer.

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.

Urinary organs-at-risk for radiotherapy following radical prostatectomy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU).

Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis.

A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer.

Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging.

The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.

Simple prostatectomy followed by radiation therapy for prostate cancer: a novel treatment pathway for men with marked prostatomegaly and prostate cancer: a series of cases.

Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.

Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.

A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection.

Treatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.

Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer.

Reproducibility of Statistically Significant Phase III Oncology Trials: An in Silico Meta-Epidemiological Analysis - Beyond the Abstract

CHD1 Loss Reprograms SREBP2-Driven Cholesterol Synthesis to Fuel Androgen-Responsive Growth and Castration Resistance in SPOP-Mutated Prostate Tumors - Beyond the Abstract

Analysis of the Current Surgical Anatomical Knowledge of Radical Prostatectomy: An Updated Review - Beyond the Abstract

Rectal Spacer Use and Bowel, Urinary, and Sexual Dysfunction Diagnosis and Related Procedures Among Men Receiving Prostate Radiotherapy: US County-Level Analysis - Beyond the Abstract

Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data - Beyond the Abstract

Integrating Genomic Classifiers and Nonsuspicious Magnetic Resonance Imaging Findings in Predictive Modelling for Lymph Node Metastasis in Patients with Localized Prostate Cancer - Beyond the Abstract

Postdiagnosis Physical Activity Is Associated with Improved Survival in Prostate Cancer Patients Treated with Surgery but Not with Radiation Therapy - Beyond the Abstract

Upper Tract Tumors

A multi-data fusion deep learning model for prognostic prediction in upper tract urothelial carcinoma.

Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.

Testicular Cancer

Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors.

Exposure to per- and polyfluoroalkyl substances during fetal development and risk of testicular germ cell cancer in adulthood.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC